Understanding Pathways to Stimulant Use: a mixed-methods examination of the individual, social and cultural factors shaping illicit stimulant use across Europe (ATTUNE): study protocol by Rosenkranz, Moritz et al.
Citation:  Rosenkranz,  Moritz,  O'Donnell,  Amy,  Verthein,  Uwe,  Zurhold,  Heike,  Addison, 
Michelle, Liebregts, Nienke, Rowicka, Magdalena, Barták, Miroslav, Petruželka, Benjamin, 
Kaner, Eileen and Martens, Marcus-Sebastian (2019) Understanding Pathways to Stimulant 
Use: a mixed-methods examination of the individual, social and cultural factors shaping illicit 
stimulant use across Europe (ATTUNE): study protocol. BMJ Open, 9 (8). e029476. ISSN 
2044-6055 (In Press) 
Published by: BMJ Publishing Group
URL:  https://doi.org/10.1136/bmjopen-2019-029476  <https://doi.org/10.1136/bmjopen-2019-
029476>
This  version  was  downloaded  from  Northumbria  Research  Link: 
http://nrl.northumbria.ac.uk/39948/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to 
access the University’s research output. Copyright ©  and moral rights for items on NRL are 
retained by the individual author(s) and/or other copyright owners.  Single copies of full items 
can be reproduced,  displayed or  performed,  and given to third parties in  any format  or 
medium for personal research or study, educational, or not-for-profit purposes without prior 
permission or charge, provided the authors, title and full bibliographic details are given, as 
well  as a hyperlink and/or URL to the original metadata page.  The content must  not  be 
changed in any way. Full  items must not be sold commercially in any format or medium 
without  formal  permission  of  the  copyright  holder.   The  full  policy  is  available  online: 
http://nrl.northumbria.ac.uk/policies.html
This document may differ from the final, published version of the research and has been 
made available online in accordance with publisher policies. To read and/or cite from the 
published version of the research, please visit the publisher’s website (a subscription may be 
required.)
1Rosenkranz M, et al. BMJ Open 2019;9:e029476. doi:10.1136/bmjopen-2019-029476
Open access 
Understanding pathways to stimulant 
use: a mixed-methods examination of 
the individual, social and cultural 
factors shaping illicit stimulant use 
across Europe (ATTUNE): 
study protocol
Moritz Rosenkranz,   1 Amy O'Donnell,   2 Uwe Verthein,1 Heike Zurhold,1 
Michelle Addison,3 Nienke Liebregts,4 Magdalena Rowicka,5 Miroslav Barták,6 
Benjamin Petruželka,6 Eileen FS Kaner,2 Marcus-Sebastian Martens1
To cite: Rosenkranz M, 
O'Donnell A, Verthein U, et al.  
Understanding pathways 
to stimulant use: a mixed-
methods examination of the 
individual, social and cultural 
factors shaping illicit stimulant 
use across Europe (ATTUNE): 
study protocol. BMJ Open 
2019;9:e029476. doi:10.1136/
bmjopen-2019-029476
 ► Prepublication history and 
additional material for this paper 
are available online. To view, 
please visit the journal (http:// 
dx. doi. org/ 10. 1136/ bmjopen- 
2019- 029476).
Received 28 January 2019
Revised 05 July 2019
Accepted 10 July 2019
For numbered affiliations see 
end of article.
Correspondence to
Moritz Rosenkranz;  
 moritz. rosenkranz@ uni- 
hamburg. de
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY. 
Published by BMJ.
Strengths and limitations of this study
 ► First study of its kind to examine different pathways 
of amphetamine-type stimulant (ATS) use and will 
thus expand an underdeveloped evidence base.
 ► Large qualitative and quantitative dataset collected 
in five European countries, which allows valuable 
intercountry comparisons.
 ► Applies a theory-based analytical framework to 
understand the individual, social and environmen-
tal influences shaping ATS use, which will provide 
important insights expedient for the development of 
tailored prevention and intervention measures.
 ► Cross-sectional design allows correlative but no 
causal conclusions.
AbStrACt
Introduction Amphetamine-type 
stimulants (ATS) including amphetamine, 
methylenedioxymethamphetamine/‘ecstasy’, 
methamphetamine, synthetic cathinones and ‘Ritalin’ are 
the second most commonly used illicit drugs globally. Yet, 
there is little evidence on which factors are associated 
with the development of different patterns of ATS use 
over the life course. This study aims to examine which 
individual, social and environmental factors shape different 
pathways and trajectories of ATS consumption. The study 
will be conducted in five European countries: Germany, the 
Netherlands, Poland, Czech Republic and the UK.
Methods and analysis We will use a sequential mixed-
methods study design to investigate the multiple factors 
(familial, social and occupational situation, critical life 
events, general risk behaviour, mental and physical 
health, satisfaction with life) that shape individual ATS use 
pathways. A systematic literature review will be performed 
to provide an overview of the current academic literature 
on the topic. In module 1, qualitative semistructured 
interviews (n=ATS users and non-users) will be conducted 
to explore individual experiences of, and perspectives on, 
dynamics of change in stimulant consumption patterns. In 
module 2, structured questionnaires (n=2000 ATS users 
and non-users) will be administered via tablet computers 
to validate and enhance the generalisability of the interview 
findings. Data integration will take place at two key points. 
First, during the study, where the findings from the first 
qualitative interviews will inform the design of the structured 
questionnaire. Second, at the end of the study, where mixed 
methods data will be brought together to generate an in-
depth, contextualised understanding of the research topic.
Ethics and dissemination The study has been approved 
by the respective responsible ethics committee in each 
participating country. Data will be treated confidentially 
to ensure participants’ anonymity. Findings will be 
disseminated in peer-reviewed scientific journals, national 
and international conferences, and in briefings for policy 
and practice.
IntroduCtIon
Amphetamine-type stimulants (ATS) are the 
second most commonly used illicit drugs 
globally1 as well as in Europe.2 ATS include 
amphetamines (‘speed’), methylenedioxy-
methamphetamine (‘MDMA’ or ‘ecstasy’), 
methamphetamine (‘crystal meth’)3 and illicit 
use of amphetamine-type prescription drugs 
(eg, ‘Ritalin’). In recent years, there has also 
been a rise in new psychoactive substances that 
mimic the effects of stimulants in global drug 
markets,4 including synthetic cathinones such 
as mephedrone (‘bath salts’). Across Europe 
as a whole, 0.5% of those aged 15–64 reported 
using amphetamines in the past 12 months, 
with higher rates for MDMA use (0.8%). 
However, ATS use rates vary by country, with 
the highest consumption found in the Neth-
erlands (amphetamine, 1.7%; MDMA, 3.6%). 
Data also suggest higher consumption rates 
for adolescents and younger adults compared 
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with the general population, with 1% of those aged 15–34 
reporting amphetamine consumption and 1.8% MDMA 
consumption, over the previous year.1 2 Worldwide, quan-
tities of ATS seized have doubled over the past decade,5 
with increased usage levels reflected in wastewater anal-
yses conducted in several European countries6 and in a 
corresponding rise in numbers of first-time entrants for 
stimulant treatment across Europe from about 7000 in 
2006 to more than 12 000 in 2016.2 Long-term use of ATS 
can lead to a substance use disorder, including (psycho-
logical) dependency.7 The global prevalence of substance 
use disorders related to amphetamines was estimated at 
nearly five million people in 2016. In Europe around 260 
000 people are affected by amphetamine use disorder, 
with prevalence twice as high in Eastern Europe as in the 
central region.8
Methamphetamine use at dependent levels is associ-
ated with multiple comorbidities, including HIV infec-
tion, hepatitis, cardiac effects, cognitive dysfunction and 
prominent psychiatric consequences such as psychosis.9 10 
Although MDMA is often viewed as a recreational drug, 
prolonged use is associated with neurological dysfunction 
and depression.11 Additional societal costs identified with 
ATS abuse include premature death, crime, lost produc-
tivity, environmental damage, disruption of family life 
and infectious disease.9 12 13 However, despite the substan-
tial harms associated with ATS use, increased prevalence 
in consumption rates and rising number of treatment 
entries, there is little evidence regarding which factors 
shape different patterns of ATS use.
Some qualitative and very few quantitative studies 
exploring influences on ATS use have been published, 
primarily focused on factors affecting initiation.14 
Important motives for the initiation of ATS consump-
tion identified in previous research include: curiosity or 
propensity for experimentation15–18; self-management of 
stress, trauma or other mental health issues16 18–24 and 
to boost of performance at work/studies19 21 25–27 or in 
private settings (sexual relationships, endurance at dance 
events).18 26 28–30 There is some evidence to suggest that 
continued and/or increased ATS consumption is often to 
support specific functional needs (improvement of stress 
management or reduced insecurity in social situations) 
and to help manage withdrawal effects.15 20 22 27 29 31–34 Expe-
riencing critical life events (separation, death of a close 
friend or family member, domestic violence) also appears 
to be associated with sustained use.19 26 32 Reported factors 
connected with a decrease (and in some cases, until absti-
nence) included an increased perception of negative 
health impacts,16 20 29 35 36 changing social networks and 
reduced availability of ATS.28 37 38 However, there remains 
limited understanding of what influences different trajec-
tories of consumption over time and whether this varies 
by type of ATS substance or user characteristics, such as 
gender, age or socioeconomic status.
In the framework of the European Research Area 
Network on Illicit Drugs, a consortium of five research 
institutions from Germany, the UK, Poland, the 
Netherlands and the Czech Republic, was formed to 
conduct a study to respond to this evidence gap. The 
European ATTUNE study (Understanding Pathways to 
Stimulant Use: a mixed-methods examination of the indi-
vidual, social and cultural factors shaping illicit stimulant 
use across Europe) is led by Germany, as the principal 
investigator.
research objectives
The overall aim of the project is to improve our under-
standing of which factors shape different pathways of ATS 
use in Europe. By examining interactions between indi-
vidual, social and environmental influencing factors, and 
the overall trajectory of drug use, this study will explore 
individual motivations to use ATS and describe different 
patterns of consumption over time. In doing so, the study 
seeks to identify potential protective factors (eg, person-
ality traits, social integration) associated with the ability 
to control, decrease or quit ATS use, as well as risk factors 
(eg, critical life events) associated with the escalation of 
ATS consumption patterns towards problematic use and/
or dependence. Further, we aim to explore why some indi-
viduals exposed to ATS select not to use these substances, 
as well as examining the relationship that illicit stimulant 
users have with other illicit and licit substances. Targeted 
recruitment of different ATS user groups with regard to 
frequency, dependency, former or current use will ensure 
a sample that varies by type and level of ATS use. Details 
about the different user groups targeted by this study are 
provided below.
MEthodS And AnAlySIS
Study design
ATTUNE is a sequential, exploratory, mixed-methods 
study. The design, implementation and interpretation 
of the study is informed by the biopsychosocial model 
of substance use.39 This model suggests that the change 
process of drug use pathways is influenced by the interac-
tion of three core domains: individual differences, social 
dynamics and the environmental/cultural setting. The 
study comprises of three main components.
First, a systematic review of the qualitative and quan-
titative published literature on which individual, social 
and environmental influences shape different pathways 
of ATS use over the life course. The qualitative literature 
review is completed and published.14 We searched four 
databases for peer-reviewed qualitative studies which 
explored the views of ATS users on which factors have 
shaped their drug use careers. The search strategy was 
conducted in accordance with the Sample, Phenomenon 
of Interest, Design, Evaluation, Research type (SPIDER) 
tool.40 Further details can be found in the corresponding 
publication. The ongoing systematic review of the quanti-
tative literature (studies on ATS use in adults and adoles-
cents) aims to appraise the evidence on risk, protection, 
resilience and desistance. Search strategy as well as data 
extraction are analogous to the qualitative review. The 
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findings from these reviews will provide an insight into 
the existing international literature that examines ATS 
users’ perspectives on why they start, stop, increase and/
or reduce their ATS consumption while also exploring 
under which circumstances and conditions stimulant 
users change their consumption patterns.
Next, in module 1 of the fieldwork, qualitative methods 
(semistructured interviews) will be used to explore indi-
vidual experiences and perspectives on dynamics of 
change in stimulant consumption patterns. The topic 
guide will build in particular on the findings from the 
review of qualitative literature conducted at the start of 
the project, as well as the theoretical underpinning for 
the research (biopsychosocial model of drug use).
Finally, in module 2, the findings from the qualitative 
interviews will inform the development of a structured 
questionnaire to validate and enhance the generalis-
ability of the results in a large sample of ATS users and 
non-users.
The total length of the study is 36 months (September 
2016 to August 2019). The estimated duration of the 
recruitment as well as data collection for module 1 is 
7 months, and for module 2 it will amount to 13 months.
Participants
Eligibility criteria
Individuals who have either used or had the opportunity 
to use ATS are eligible for inclusion in both the quali-
tative interviews and survey questionnaire. This includes 
people who have either consumed ATS at least once in 
their life or people who have never used ATS but have 
been exposed to ATS consumption (defined as having 
been present when family or friends took ATS but refused 
to consume themselves). To ensure the inclusion of 
only those who have had the opportunity to experience 
changes in the trajectory of their ATS use, the partici-
pant’s first ATS consumption (or exposure) needs to have 
taken place at least 5 years before the interview or survey 
questionnaire. We also excluded people previously diag-
nosed with opioid dependence (self-reported) to avoid 
overlap between pathways to opioid use and pathways to 
ATS use. Excluding these participants also ensures that 
our sample is not dominated by former or current opioid 
users who consume stimulants primarily to complement 
their opioid use (eg, to get a ‘kick’ while in opioid substi-
tution therapy).
Further inclusion criteria
 ► Aged 18 years or older.
 ► Resident in one of the five national sampling regions.
 ► Able to take part in the interview (not psychotic, no 
severe cognitive impairments or language barriers).
A screening website will be set up where interested 
persons can check their eligibility to participate in an 
interview or survey questionnaire. If a person is screened 
successfully, a message is displayed inviting the person to 
participate and offering different possibilities to contact 
the research team to arrange an interview appointment. A 
randomly chosen screening ID facilitates the connection 
of the screening data with the interview while maintaining 
anonymity.
Study groups
Participants in both modules 1 and 2 will be recruited 
using convenience sampling (see below). To ensure a 
sufficient variety of ATS use patterns or ATS use trajecto-
ries, six study groups were predefined for module 1 and 
five study groups for module 2. This approach provides a 
stratified sample, in which each ATS use pattern (group) 
serves as a stratum.
Module 1: Qualitative semistructured interviews
Eligible participants meeting the above criteria will be 
allocated to one of six study groups depending on their 
ATS consumption patterns (time, frequency, depen-
dency). Table 1 shows an overview of the operationalisa-
tion of the six groups.
We defined the current use as ATS consumption within 
the previous 12-month period. Frequent use was defined 
as those reporting ATS consumption on 10 or more occa-
sions (consumption days) during the previous 12 months 
(groups 1 and 3) or any 12-month period prior to the past 
year (groups 2 and 4). ATS dependency was assessed using 
the Severity of Dependence Scale (SDS).41 We chose a 
cut-off of 4 points or more to identify ATS dependency.42
Module 2: Survey questionnaire
Eligible participants meeting the above criteria will be 
allocated to one of five study groups depending on their 
ATS consumption patterns (time, frequency, depen-
dency). table 2 shows an overview of the operationalisa-
tion of the five groups. To allow us to distinguish clearly 
between the current and previous use, we defined the 
current use as ATS consumption in the past 3 months and 
the former use as no consumption in the past 12 months. 
This means that participants reporting ATS use over 3 but 
less than 12 months previously are excluded.
Sample size
Module 1: Qualitative semistructured interviews
Forty-five persons per study group (n=270 for the total 
sample, see table 3) were considered sufficient for module 
1.43 As we plan to recruit participants via purposeful 
sampling,44 we expect to generate data that are rich 
enough to answer our research questions and inform the 
questionnaire used in module 2 of the study.
Module 2: Survey questionnaire
Statistical analyses within the group of current users (A_1 
and A_2) as well as within the group of former users (B_1 
and B_2) are planned (see table 2). To facilitate this at 
country level, a group size of n=100 is sufficient to detect 
statistically significant small to medium effects for contin-
uous distributed variables (d≥0.40, α=0.05, power=80%).45 
The sample sizes of the groups are planned as follows. 
For both, groups A and B, up to 200 participants in 
each country will be recruited. This allows us to analyse 
subgroups, for example, dependent and non-dependent 
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Table 1 Operationalisation of study groups in module 1
Study 
groups in 
module 1 Name
Past 12 
months 
prevalence
≥10 consumption 
days within past 
12 months
≥10 consumption 
days within 
1 year (at any 
time except past 
12 months)
Currently ATS 
dependent
Formerly ATS 
dependent
Group 1 Currently dependent 
users
Yes Yes n.a. Yes n.a.
Group 2 Formerly dependent 
users
n.a. n.a. Yes No Yes
Group 3 Currently frequent, non-
dependent users
Yes Yes n.a. No No
Group 4 Formerly frequent, non-
dependent users
No n.a. Yes No No
Group 5 Non-frequent users 
(currently or formerly)
No n.a. No No No
Group 6 Exposed non-users n.a. n.a. n.a. n.a. n.a.
Module 2: Survey questionnaire.
ATS, amphetamine-type stimulant.
Table 2 Operationalisation of study groups in module 2
Study groups 
in module 2 Name
Past 12 months 
prevalence
Past 3 months 
prevalence
≥10 consumption 
days within past 12 
months
≥10 consumption 
days within 1 year 
(at any time except 
past 12 months)
Group A_1 Currently frequent 
users
Yes Yes Yes n.a.
Group A_2 Currently non-frequent 
users
Yes Yes No n.a.
Group B_1 Formerly frequent 
users
No n.a. n.a. Yes
Group B_2 Formerly non-frequent 
users
No n.a. n.a. No
Group C Exposed non-users n.a. n.a. n.a. n.a.
users in groups A as well as B. As group C consists of 
non-users only, the analyses will focus on comparison with 
one of the user groups (A or B), reducing the required 
size for this group to n=100. The total sample size for 
module 2 for all countries will amount to 2000 persons 
(see table 4). Due to funding restraints, the sample size in 
the Netherlands and the Czech Republic is smaller, which 
might impede the production of statistically significant 
country specific intragroup comparisons.
recruitment
Sampling method and recruitment procedure
Participants in both modules will be recruited by 
non-probability (convenience) sampling, which is an 
accepted means of accessing participants from ‘hard-to-
reach’ as well as minority populations.46 47 Preidentified 
sampling areas in each participating country (see tables 3 
and 4) are designed to include participants living in 
urban as well as rural areas.
Multiple methods and sites will be employed to identify 
and recruit participants for both modules. Leaflets and 
posters containing information about the study, a link to 
the screening website and contact details of the research 
teams will be printed and distributed in substance use 
help and treatment facilities, on university black boards, 
in head shops, bars and nightclubs. Social media and 
substance use web forums will be used to share and circu-
late the request for participants. Participants will also be 
recruited actively at university campuses, drug service 
facilities and music festivals by directly approaching 
potential participants. All interested interviewees will be 
screened for eligibility prior to the interview. If eligible 
to participate, each respondent will receive a screening 
code, and the interview can either be conducted straight 
away or an appointment can be made for a later date. 
At the end of each interview, participants will be asked 
to recruit further participants from their social network. 
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Table 3 Sample sizes module 1 by countries and study groups
Country
Partner 
institution Data collection regions
Sample sizes
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
Total N 
countries
Currently 
dependent
Formerly 
depen-
dent
Currently 
frequent, 
non-
dependent
Formerly 
frequent, 
non-
dependent
Non-
frequent 
(currently 
or 
formerly) Exposed
Germany ZIS Border region to Czech 
Republic /metropolitan 
region of Hamburg
10 10 10 10 10 10 60
UK UNEW Northern England 10 10 10 10 10 10 60
Poland APS Metropolitan region of 
Warsaw
10 10 10 10 10 10 60
Netherlands RG Amsterdam/the region of 
Eindhoven
10 10 10 10 10 10 60
Czech 
Republic
OGCR Border region to 
Germany
5 5 5 5 5 5 30
Total N groups 45 45 45 45 45 45 270
APS, The Academy of Special Education, Warsaw; OGCR, Office of the Government of the Czech Republic; RG, De Regenboog Groep, Amsterdam; 
UNEW, Institute of Health and Society, Newcastle University; ZIS, Centre of Interdisciplinary Addiction Research of Hamburg University.
This additional snowball sampling approach will be 
realised by handing over study leaflets, as well as up to 
three numbered cards containing contact details of the 
research team. The numbers on the cards will help to 
track the snowball sampling approach.
Procedure
Fieldwork
Module 1
Face-to-face semistructured interviews will be conducted 
by members of the research team of each participating 
country. Prior to the interview, all participants will receive 
an information leaflet containing details about the study, 
explaining what participation involves: anonymity, confi-
dentiality, the use of data and data protection rules. The 
participants will then be invited to complete a verbal 
consent form, should they wish to participate. The inter-
view will be audio recorded and will last approximately 
45 to 60 min. On completion of the interview, each 
participant will receive an incentive (money or vouchers, 
depending on country). All interviews will be transcribed 
in full, transferred to appropriate software for analysis, 
and the audio file deleted.
Module 2
The quantitative survey will be conducted with the 
computer-assisted personal interviewing method. The 
questionnaire content will first be developed in Microsoft 
Word. Once finalised, all questions will be programmed 
using survey software GessQ to enable administration via 
password-protected tablet computers. The survey instru-
ment will be translated and piloted in all partner coun-
tries and revised as necessary. The latest version of the 
questionnaire will be hosted on a central server operating 
in the information technology environment of Hamburg 
University and can be downloaded to the tablets directly 
as necessary. This server is also the recipient for the data 
uploads from the tablets.
In each country, trained research assistants will recruit 
participants and conduct the interviews face-to-face or 
via video-telephony (Skype). Show cards containing rele-
vant prompts and additional information (eg, lists of 
ATS, answering scales) will support the conduct of the 
interviews.
Monitoring and data management
The screening process and fieldwork progress will be 
monitored using a study-specific coordination database. 
This database will be populated with screening data from 
each participant as well as key information regarding the 
interviews or questionnaires, such as study group, dura-
tion of interview, gender distribution, sampling region 
and contact with drug help services.
Module 1
The raw qualitative data from module 1 will be managed, 
stored and analysed by the respective research teams 
in each participating country. Initial analyses will be 
conducted at country level using a common coding 
framework. Analysed data, including emerging inter-
view themes, will be pooled and provided to ATTUNE PI 
(Hamburg University).
Module 2
The raw quantitative data will be uploaded continuously 
to the central data management at the Hamburg Univer-
sity. The raw data will be cleaned, edited and transformed 
into SPSS datasets, one for each country, as well as one 
comprehensive dataset covering all five countries.
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Survey instruments
Module 1: Interview guideline and time sheet
Two semistructured interview guides will be used to 
conduct the in-depth interviews in module 1: one for 
the ATS user groups plus an adapted topic guide for the 
non-user group. The topic guide will be based on key 
emergent themes from the systematic literature review as 
well as relevant theoretical considerations (biopsychoso-
cial model of substance use). Participants will be asked 
about their experiences and their consumption patterns 
regarding ATS and other licit and illicit drugs. To obtain a 
detailed understanding of which influences have shaped 
these ATS use patterns, participants will be asked about 
drug use motives, effects/consequences, settings and 
occasions and how these have changed during the peri-
od(s) in life where ATS use took place. The interview will 
end with questions about the (social) setting of use and 
its impact and the integration of ATS use into the respon-
dent’s lifestyle. The interview guidelines are provided 
in the online supplementary material. While the use of 
the interview guide will ensure that all central topics are 
covered, participants will have the opportunity to discuss 
additional issues or concerns where relevant. During the 
interviews, researchers will chart participants substance 
use over time, including age of onset, frequency and 
life stage, as well as positive and negative life events (eg, 
family/partnership, education/work, illness, treatment, 
imprisonment).
Module 2: Quantitative questionnaire
The quantitative survey questionnaire will include ques-
tions based on the key themes emerging from the qual-
itative interviews, as well as a selection of standardised 
instruments to assess various substance use, health and 
psychological factors (see table 5).
The questionnaire will cover:
a. Sociodemographics: These include sex, age, citizen-
ship, migration background, relationship and chil-
dren, living situation, educational and occupational 
situation and social integration.
b. Drug use: Detailed assessment of all illicit drugs ever 
used in life (lifetime prevalence, past 12-month prev-
alence, past 30-day prevalence, age at first and last 
use), test for alcohol dependence (Cutting Down, 
Annoyance by criticism, Guilty feeling, Eye-Openers 
(CAGE); Alcohol Use Disorders Identification Test-
Consumption (AUDIT-C)) and tobacco smoking 
status.
c. ATS use: Test for ATS dependence (SDS), injecting 
drug use and treatment experiences; usual setting of 
ATS use; patterns, motives and consequences of ATS 
use including (reasons for) changes.
d. Judicial problems: times and reasons for imprisonment.
e. Physical and mental health assessment (Brief Symptom 
Inventory-18).
f. Personality assessment (Big Five Inventory-10, Brief 
Sensation Seeking Scale-4, Generalized Self-Efficacy 
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Scale, Connor-Davidson Resilience Scale-10) and crit-
ical life events.
For group C (non-users), some questions will be omitted 
(eg, questions about ATS use) and replaced with alterna-
tive questions focused on their motives for non-use and 
exposure situation.
Planned analyses
Module 1
Qualitative data from the semistructured interviews will 
be analysed using content analysis and conducted with 
appropriate software, such as MAXQDA48 or NVivo.49 
Partners will develop a common, unified coding system 
to facilitate comparable findings from the interviews 
across all partner countries. In addition, the data 
collected with the timeline and chart on substance use 
and life events will be merged and analysed systemati-
cally. Each partner will conduct initial country-level 
analysis separately in the respective national language. 
Once this initial analysis has been completed, each 
partner will produce a report detailing the country-level 
findings in English and following a common template. 
These reports will then be compiled and synthesised to 
produce a comprehensive, cross-national analysis of the 
qualitative interviews.
Module 2
The quantitative data analysis will be conducted using 
the statistical software package SPSS V.22.50 Descrip-
tive, univariate analyses will be used to describe the 
sociodemographics, health and personality assessment 
characteristics of the sample, alongside ‘consumption 
careers’ (substance use, motives of use and changes of 
use patterns). Independent sample t-tests and χ2-anal-
yses, corrected for multiple testing, will be conducted 
to compare gender and age characteristics among the 
ATS user groups. Multivariate approaches will be used to 
assess a wide range of factors derived from the biopsycho-
social model regarding their possible influence on ATS 
use patterns. So, for example, by calculating a multivar-
iate analysis of variance (MANOVA), we can simultane-
ously test if an individual factor like resilience, a social 
factor like social integration and an environmental factor 
like ATS availability is associated with the number of ATS 
consumption days, the number of cannabis consump-
tion days and the mental health condition index. 
Furthermore, the MANOVA allows us to detect interac-
tions between the dependent variables. When it comes 
to an exploration of different ATS user groups such as 
frequent users, non-frequent users and non-users, we will 
apply a multinomial logistic regression and determine 
the association between for example, traits and being a 
member of one of those groups. If data permit, we will 
calculate latent class analyses to identify ATS user groups 
which characteristics are unknown yet. Analyses will be 
conducted at country level, as well as across the full Euro-
pean sample.
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Patient and public involvement
Patients and members of the public will be involved in 
ATTUNE at various stages of the study. Policy makers, 
European non-governmental organisations and service 
users helped shape the design and focus of the study 
prior to obtaining funding. We will hold information/
discussion sessions about the study with statutory and 
non-statutory service providers to acquire their insights 
into how the findings could potentially impact and shape 
the everyday lives of their service users. Recruited partic-
ipants enrolled into the study will be invited to act as 
‘seeds’ for the snowball sampling of additional survey 
interview subjects. This inclusion of patients/public in 
this way helps with enhanced recruitment and enables 
these participants to share their experiences of taking 
part with others and to underline the importance of the 
study to people like themselves. ATS user representatives 
and public representatives will be actively involved in 
disseminating the results of the research.
Ethics and dissemination
Based on the regulations in each participating country, 
ethical approval was obtained. Participant anonymity will 
be maintained in both the semistructured interviews and 
the survey questionnaire. During the survey, no informa-
tion will be collected that could link the data to the partic-
ipant concerns. All participants will be explicitly asked 
to provide informed consent to taking part in the study 
and made aware of the data protection rules. A written 
informed consent form, signed by the project leader, will 
be made available to each participant before the inter-
view. Verbal consent in module 1 will then be asked for, 
recorded and documented in the transcription of the 
interview. The quantitative interview (module 2) starts 
with the question, if the participant has read the informed 
consent form and if she/he is willing to give consent. 
The information about each participant’s consent will be 
saved in a dedicated variable of the dataset.
Research findings of ATTUNE will be disseminated in 
peer-reviewed, open-access journals as well as at national 
and international conferences and workshops. Each 
partner will also deliver reports to their funding institu-
tions under the specific terms of the respective country. 
Additionally, an accessible report will be drafted and 
distributed to organisations who express an interest in 
the study. A specific report that is accessible to substance 
users will be developed for individuals. We intend to 
disseminate these findings through social media to maxi-
mise impact and expand networks of interest.
Strengths and limitations of this study
By using multiple methods (systematic literature reviews, 
qualitative interviews and survey questionnaires), this 
study will generate in-depth, contextualised evidence 
in an underexplored field of research. The use of strat-
ified sampling will ensure a sufficient variety of types 
of ATS users and non-users are included, reflecting 
different use patterns, current and ex-users, dependent 
and non-dependent users as well as exposed non-users. 
In particular, the views and experiences of non-users 
are rarely reflected in the evidence base and could help 
generate novel insights into which factors shape decisions 
not to consume ATS. The application of standardised 
interview guides and questionnaires will result in a large 
comprehensive sample that will allow us to compare ATS 
use in multiple and varied sociocultural, political and 
legal environments across Europe.
A key limitation of the study is the cross-sectional design, 
which makes it difficult to trace pathways and trajectories 
of ATS use over time. We address this by only including 
persons, whose first contact with ATS consumption 
occurred at least 5 years ago, meaning they have had the 
chance to develop different ATS use patterns. However, it 
is important to stress that a cross-sectional design allows 
correlative but no causal conclusions. One further issue 
concerns the convenience sampling approach employed 
in this study in predefined sampling regions. At the same 
time, compared with representative general population 
surveys, our method should ensure increased levels of 
inclusion of different ATS user types, allowing for more 
detailed and in-depth insights into different use trajecto-
ries. Finally, by defining multiple inclusion criteria as well 
as precise group strata, we aim to mitigate potential bias 
that could emerge from this sampling approach.
IMPlICAtIonS for IntErvEntIonS And futurE PolICy
The findings from this research will enable policy makers 
and practitioners to improve existing ATS prevention 
and intervention programmes and support the devel-
opment of new approaches in the future. By examining 
different types of stimulant users (including ex-users and 
non-users), information will be generated which will be 
important for universal prevention (targeting general 
populations), selective prevention (focussing on vulner-
able groups) and indicated prevention (aiming at groups 
that show early signs of problematic substance use). 
Furthermore, given the limited long-term efficacy of ATS 
treatment,51 the findings of this study could support the 
development of ATS treatment programmes that are 
more effectively tailored to the needs of specific ATS 
populations and individual users.
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